Sign up to save your podcasts
Or
Share Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By The Wall Street Journal & Spotify Studios
4.2
54235,423 ratings
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Journal.
View all
WSJ Tech News Briefing
1,646 Listeners
WSJ What’s News
4,328 Listeners
WSJ Your Money Briefing
1,714 Listeners
Planet Money
30,651 Listeners
WSJ Opinion: Potomac Watch
2,813 Listeners
Acquired
4,239 Listeners
The Daily
110,854 Listeners
WSJ Minute Briefing
663 Listeners
Bold Names
1,448 Listeners
Post Reports
5,418 Listeners
Hard Fork
5,466 Listeners
The Ezra Klein Show
15,529 Listeners
The Big Take
157 Listeners
Bad Bets
1,322 Listeners
WSJ Opinion: Free Expression
594 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
127 Listeners